Hemorrhage Stroke Articles & Analysis: Older
14 news found
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with Chronic Kidney ...
TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels during an ischemic stroke. It is the only device that adjusts to the vasculature and clot, a more atraumatic approach than existing devices. ...
” About Rapid Medical Rapid Medical develops the premier, responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. ...
“We know from large vessel ischemic stroke that restoring blood flow to the brain as quickly as possible provides greatly improved outcomes. Now that we have the technology to reach distal strokes with TIGERTRIEVER 13, we must understand the patient benefit in quickly opening smaller blood vessels as ...
In clinical studies, when dosed up to four times daily, TSC has been demonstrated safe and tolerable in more than 180 patients included in trials across a variety of indications including patients with glioblastoma multiforme brain cancer (“GBM”), peripheral artery disease with intermittent claudication, stroke, and COVID-19. In pre-clinical data, TSC has been ...
ByCervoMed
AI-powered neuroscience solutions for intracranial hemorrhage, ischemic stroke, cervical spine fractures, on display at ISC 2022, New Orleans, February 9-11, Booth #801 New York, February 8, 2022 – Aidoc, the leading provider of healthcare AI solutions, will be delivering a live demonstration of its comprehensive AI care coordination suite at ISC 2022, ...
ByAidoc
” “When diagnosing and treating critical pathologies like pulmonary emboli and hemorrhagic strokes, every second counts,” said Dr. Eric Eskioglu, Executive Vice President Chief Medical and Scientific Officer, Novant Health. ...
ByAidoc
Delivering value to nearly 600 medical centers across the globe, Aidoc’s suite of AI solutions enable radiologists to expedite patient treatment and improve quality of care by flagging acute anomalies such as pulmonary embolism, intracranial hemorrhage, and stroke – in real time. Aidoc’s inclusion of a full breast imaging AI solution with ...
ByAidoc
Aidoc’s solutions enable radiologists to expedite patient treatment and improve quality of care by immediately flagging acute anomalies such as pulmonary embolism, intracranial hemorrhage, and stroke – in real time. Riverain developed the first concurrent read FDA cleared algorithm for the early and efficient detection of lung disease. ...
ByAidoc
Clinical trial underway at five US hospital sites to evaluate Sense’s novel, non-invasive brain scanner to monitor intracranial hemorrhage in acute hospital setting Drug Controller General of India (DCGI) and Health Canada grant permission to conduct clinical trial at multiple sites in India and Canada Current standard of care lacks a means to monitor brain injury ...
“Thousands of stroke survivors require rehabilitation each year. Today’s authorization offers certain chronic stroke patients undergoing stroke rehabilitation an additional treatment option to help them move their hands and arms again and fills an unmet need for patients who may not have access to home-based stroke ...
Davis will oversee the growth of the company’s technology portfolio for the treatment of ischemic and hemorrhagic stroke. He will retain his role as COO and join the company’s Board of Directors. ...
As a result, we have expanded our key 021 platform so that it can deliver a wider range of devices than it was originally designed for including stents, braided flow diverters and stentrievers, for treatment of both hemorrhagic and ischemic strokes. In particular, the 021 ensures predictable stability and control when delivering the larger and braided devices ...
Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the latest advances in neurovascular devices treating ischemic and hemorrhagic strokes. The round was co-led by new investors Ally Bridge Group and Bain ...